Volkher Scharnhorst

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM This study explores clinical outcome in cytochrome P450 2C19 (CYP2C19)-related poor metaboliser patients treated with either clopidogrel or prasugrel after percutaneous coronary intervention (PCI) and investigates whether this could be cost-effective. METHODS AND RESULTS This single-centre, observational study included 3260 patients scheduled for(More)
  • 1